Protalix BioTherapeutics to Present at 3 Healthcare Conferences
Do you know when to trade PXBT ?
PXBT | Quote | Chart | News | PowerRating -- Protalix BioTherapeutics, Inc., announced that Dr. David Aviezer, the Company's President and Chief Executive Officer, will be presenting at 8th Annual Needham Life Sciences Conference in New York and the 8th National Life Science and Technology Week ISLI-Biomed Israel 2009.
Additionally, Dr. Einat Brill Almon, the Company's Senior Vice President of Product Development, will be presenting at the 3rd International Conference on Plant-Based Vaccines & Antibodies in Italy.
In a release, the company noted event details:
The conference schedule is as follows:
8th Annual Needham Life Sciences Conference: Healthcare Today & Tomorrow Corporate Presentation, June 10 at 2:30 PM ET New York Palace Hotel, New York, NY
A webcast of this presentation will be available at protalix.com
3rd International Conference on Plant-Based Vaccines & Antibodies Presentation entitled, "'Novel enzyme replacement therapy for Gaucher disease: Ongoing Phase III trials with recombinant human glucocerebrosidase expressed in plant cells," June 15 at 2 PM CET University of Verona, Verona, Italy
8th National Life Science and Technology Week ISLI-Biomed Israel 2009
Corporate Presentation, June 16 at the BioPharma Session, 4:20-6:20 PM IDT David Intercontinental Hotel, Tel-Aviv, Israel
Protalix is a biopharmaceutical company.
((Comments on this story may be sent to health@closeupmedia.com))
For full details on (PXBT) PXBT. (PXBT) has Short Term PowerRatings at TradingMarkets. Details on (PXBT) Short Term PowerRatings is available at This Link.
- Protalix begins Phase I trial of human acetylcholinesterase product candidate - 03/18/10
- Protalix Initiates a Phase I Clinical Trial of Acetylcholinesterase for Biodefense Indications - 03/17/10
- Protalix Appoints Mr. Zeev Bronfeld Interim Chairman of the Board of Directors - 03/09/10
- Protalix Announces Successful GMP Manufacturing Audit by Israel's Ministry of Health - 03/03/10
- Zacks Analyst Blog Highlights: Genzyme Corporation, Shire plc, Protalix BioTherapeutics Inc., Hospira, Inc. and XTO Energy - 02/18/10
- More News >>


